Navigation Links
Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Date:10/23/2007

fesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in nearly 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna, and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, those related to the expectation that the results from The RESILIENT Trial will establish the LifeStent self-expanding stent as a treatment alternative for certain patients. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experiences to differ materially from that expressed or implied by the forward-looking statements include those risks detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2006.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademar
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Ortho Clinical ... has been named Chief Corporate Brand and Communications Officer, ... executive leadership team, Bouryal will lead the company,s worldwide ... on its transition to an independent company by adding ... to Chairman and Chief Executive Officer Dr. Martin ...
(Date:8/3/2015)... 3, 2015   ConvergeHEALTH by Deloitte ... Allergan plc is expanding its year-long research ... Healthcare to include women,s health.  ... platform to generate real-world clinical insights in an ... look forward to expanding our work with Allergan ...
(Date:8/3/2015)... , August 3, 2015 ... is expected to reach USD 24.7 billion by ... View Research Inc. Growing prevalence of neurological and ... equipments market over the forecast period. The presence ... and cryotherapy, advancement in the technologies coupled with ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
(Date:8/4/2015)... , ... August 04, 2015 , ... The results of ... treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were published on ... Ophthalmology. According to the results of the trial, the implant, more commonly known as ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... ... 2015 , ... The Law Offices of Ben C. Martin , based ... Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter lawyer for the ... clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices and Products ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing Education Company ... of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing ... Learning Institute Inc. and EDUmotion US LLC. , This special activity was recently ...
(Date:8/4/2015)... ... , ... Mr Didier Cauchois, CIO of information systems at ... Mr Cauchois attributes the success to the dedication from the team at COL, ... offered by Winscribe's platform. , "We have already begun to see the ...
Breaking Medicine News(10 mins):Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... to a small-scale, in-office, observational study, psychiatrists and ... of pediatric ADHD and psychiatric comorbidities, particularly regarding ... which utilized accepted sociolinguistic methodologies to evaluate the ... presented recently at the 20th annual U.S. Psychiatric ...
... symptoms at least once a week, survey shows , , THURSDAY, ... how well asthma patients in the United States think they ... their daily lives, according to a survey released Thursday by ... of the survey respondents said they have their asthma symptoms ...
... that as HIV treatment improved and as HIV-related public ... disease and seek care, that HIV-infected patients would seek ... are actually sicker when they begin therapy. The study ... Infectious Diseases, currently available online. , The study, carried ...
... 25 Cash Technologies, Inc.,(Amex: TQ ... Claim-Remedi,Services, Inc. has entered into a Services ... to incorporate Claim-Remedi,s products into,TriCap,s ARxChange(TM) debt ... centralized on-line marketplace for the disposition of,healthcare ...
... Developer of Zone Sonography(TM) ... ... Systems,a developer of premium ultrasound systems and proprietary Zone,Sonography(TM) technology, announced ... financial officer (CFO). Marcotte has,more than 20 years of finance and ...
... DENVER, Oct. 25 Medical Simulation Corporation (MSC),announces ... Health,System to provide simulation training and education services ... the system,s,flagship facility, the Hospital of the University ... Report as one of the top 18 hospitals ...
Cached Medicine News:Health News:Psychiatrists, parents significantly differ in ADHD, psychiatric comorbidities perceptions 2Health News:Most Asthmatics Don't Have Illness Under Control 2Health News:Most Asthmatics Don't Have Illness Under Control 3Health News:HIV patients sicker when seeking care than in the past 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 3Health News:ZONARE Names Marcotte Chief Financial Officer 2Health News:Medical Simulation Corporation Announces Partnership With University of Pennsylvania Health System 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: